- TRYPTYR (acoltremon ophthalmic solution) 0.003%, approved by the U.S. FDA in May 2025, is a first-in-class transient receptor potential melastatin type 8 (TRPM8) receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease1
- Expanding patient offerings, SYSTANE PRO Preservative-Free (PF) is clinically proven to provide up to 12 hours of dry eye symptom relief, and PRECISION7 sphere and toric contact lenses are now commercially available across the U.S.
- MARLO announces two new advancements to help streamline operations: Mirror Import and a new partnership with RevolutionEHR
Alcon will highlight a robust pipeline of innovations across pharma, over-the-counter products, and contact lens offerings at Optometry’s Meeting (AOA) 2025, June 25-28 at the Minneapolis Convention Center.
Through education and unique events, eyecare professionals (ECPs) will gain deeper insights into how Alcon’s latest innovations can help transform their practices.
“Following a year of tremendous innovation, including regulatory approvals and launches, Alcon is proud to showcase our latest portfolio of offerings at Optometry’s Meeting,” said Kristen Brotherson, general manager, U.S. Vision Care. “From innovative developments in dry eye treatment to the full rollout of our next generation of contact lenses, AOA offers a dynamic stage on which to deliver new advancements and reaffirm Alcon’s commitment to patient-focused innovation across the industry.”
The power of natural tears in the treatment of dry eye disease
Attendees will get a first look at Alcon’s latest dry eye disease treatment TRYPTYR (acoltremon ophthalmic solution) 0.003%, which was approved for the treatment of the signs and symptoms of dry rye disease by the U.S. FDA in May 2025.
This regulatory approval is supported by two phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of Dry Eye Disease.2,3 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14 than patients not using TRYPTYR, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p<0.0001).2,3 Consistent results were observed at all timepoints through Day 90. TRYPTYR demonstrated statistically significant natural tear production as early as Day 1.2,3 TRYPTYR will be commercially available across the U.S. in the third quarter of 2025.
Alcon’s booth will serve as a resource for ECPs interested in learning more about the latest dry eye innovation. Additional information can also be found at https://tryptyr.myalcon.com/professional/.
Solidifying Alcon’s Legacy as the #1 global consumer brand of artificial tears4
This year’s attendees will also experience the full breath of Alcon’s dry eye portfolio, including the latest addition to the SYSTANE family of artificial tears, SYSTANE PRO PF. This over-the-counter lubricating eye drop, which launched in early 2025, is now clinically proven to provide up to 12 hours of dry eye symptom relief.5* As SYSTANE’s longest-lasting formula, SYSTANE PRO PF is a triple action, preservative-free formula that hydrates, restores and protects dry eyes, helping to lock in moisture and reduce tear evaporation.5,6**
The study findings demonstrate SYSTANE PRO PF’s clinical efficacy and safety in patients with mild to moderate dry eye disease, including those with aqueous deficient dry eye, evaporative dry eye and mixed dry eye.5
Optometry’s Meeting Premier of PRECISION7 1-Week Contact Lenses
The 2025 launch of PRECISION7 marks the newest addition to the Alcon WaterInnovations portfolio of contact lenses. PRECISION7 sphere and toric contact lenses are now commercially available in the U.S., allowing patients to experience this first-of-its-kind contact lens with Alcon’s novel and proprietary ACTIV-FLO System.
The ACTIV-FLO System in PRECISION7 is a unique combination of a water-loving moisturizing agent embedded in the lens matrix and a proprietary replenishing agent that is continually released to moisturize the surface for 7 days.7,8
Attendees will learn more about this technology and how it can provide their patients with 16 hours of outstanding comfort and precise vision, even on Day 7.9
Introducing Two New MARLO Advancements for Enhancing Provider and Patient Experiences
Alcon’s digital platform, MARLO, built to keep patients and reorders in the practice, is excited to announce two major developments that mark a new chapter in innovation for MARLO patients and practices.
MARLO’s latest feature, Mirror Import, is designed to streamline patient entry into MARLO. This feature helps the practice capture order data points from their Electronic Health Records (EHR) and Point of Service (POS) to automatically populate selected order information, saving the practice time by reducing manual-entry errors. Mirror Import provides flexibility to MARLO users that do not want EHR integration and will be made available to all membership levels.
In addition to this exciting product feature, Alcon is thrilled to announce a new partnership with RevolutionEHR, a leader in cloud-based EHR solutions for ECPs. This collaboration is designed to further elevate the MARLO experience, empowering practices that use RevolutionEHR to streamline patient entry into MARLO with full EHR integration. Alcon plans to bring this offering to eye care practices this summer.
At this year’s meeting, attendees can participate in Alcon and Ophthalmic World Leader’s (OWL) joint event “Opening Eyes, Opening Doors: The Strength of Saying Yes,” on Thursday, June 26, at the Hilton Minneapolis at 5:30 p.m. CT. In addition to sponsoring events throughout Optometry’s Meeting, Alcon invites attendees to experience these innovations in-booth while enjoying exclusive offerings, such as interactive iris art, MARLO demonstrations and more.
For more information on Alcon’s latest data, innovations and events at the 2025 Optometry’s Meeting, stop by booth #721 or visit https://www.myalcon.com/professional/ to learn more about Alcon’s latest advancements across contact lens and dry eye treatments.
INDICATIONS AND USAGE
TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).
Please click here for the TRYPTYR Full Prescribing Information.
Important Information for Product PRECISION7 (serafilcon A) Contact Lenses
For daily wear or extended wear up to 6 nights for near/far-sightedness. Risk of serious eye problems (i.e., corneal ulcer) is greater for extended wear. In rare cases, loss of vision may result. Side effects like discomfort, mild burning or stinging may occur.
See product instructions for complete wear, care and safety information.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
*47% of patients experience meaningful symptom relief at 12 hours, N = 153.
**In vitro data.
References
TRYPTYR U.S. FDA Prescribing Information. 2025.
Data on File for COMET-2 Phase 3 Study. Alcon 2025.
Data on File for COMET-3 Phase 3 Study. Alcon 2025.
IQVIA Consumer Health Customized Insights.
Alcon data on file, 2025.
Alcon data on file, 2024.
Zheng Y, Dou J, Wang Y, et al. Sustained release of a polymeric wetting agent from a silicone-hydrogel contact lens material. ACS Omega. 2022;7(33):29223-29230. doi: 10.1021/acsomega.2c03310.
Phan CM, Chan VWY, Drolle E, et al. Evaluating the in vitro wettability and coefficient of friction of a novel and contemporary reusable silicone hydrogel contact lens materials using an in-vitro blink model. Cont Lens Anterior Eye. 2024.
In a 2-week prospective clinical study in the U.S.; n=181; CLEAR CARE Cleaning & Disinfecting Solution used for cleaning and disinfection; Alcon data on file, 2023.